Clinical Trials, Containment, Genotoxicity and HR

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Clinical Trials

Containment

Genotoxicity

PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027

The Pharma Data

FEBRUARY 8, 2021

IBRANCE is indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men; or with fulvestrant in patients with disease progression following endocrine therapy. 2,3 In the U.S.,

HR Clinical Trials Clinical Trials Containment

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

APRIL 14, 2021

Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. FOSTER CITY, Calif.–(BUSINESS

Genotype

Genotype Containment FDA Approval Genotoxicity

Clinical Research Informer

PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

Stay Connected